Cargando…

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming

SIMPLE SUMMARY: Outcomes for patients with osteosarcoma have remained stagnant for more than 3 decades. Novel therapeutic agents are desperately needed. Osteosarcoma cells often express abnormal form of the p53, p63, and p73 genes, which promote glucose uptake, cell glycolysis, and rapid proliferati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuanzheng, Peng, Zhanglong, Flores, Elsa R., Kleinerman, Eugenie S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454976/ https://www.ncbi.nlm.nih.gov/pubmed/36077845 http://dx.doi.org/10.3390/cancers14174310

Ejemplares similares

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma
por: Yang, Yuanzheng, et al.
Publicado: (2015)

Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
por: Bhagat, Anchit, et al.
Publicado: (2022)

Combination of NK cells therapy and oral administration of entinostat as an approach for osteosarcoma lung metastasis treatment
por: Kiany, Simin, et al.
Publicado: (2015)

Osteosarcoma Overview
por: Lindsey, Brock A., et al.
Publicado: (2016)

Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma
por: Rao-Bindal, Krithi, et al.
Publicado: (2011)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion
por: Zhou, Zhichao, et al.
Publicado: (2020)

Exercise Inhibits Doxorubicin-Induced Damage to Cardiac Vessels and Activation of Hippo/YAP-Mediated Apoptosis
por: Tao, Rong-Hua, et al.
Publicado: (2021)

Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS
por: Yuan, Yu, et al.
Publicado: (2017)

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions
por: Wolf-Dennen, Kerri, et al.
Publicado: (2020)

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
por: Safaeian, Leila, et al.
Publicado: (2020)

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells
por: Wu, Xinghuo, et al.
Publicado: (2017)

Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
por: Pullman, John, et al.
Publicado: (2006)

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009)

Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats
por: Maikawa, Caitlin L., et al.
Publicado: (2021)

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide
por: Nuñez-Diaz, Cristina, et al.
Publicado: (2023)

Author Correction: Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
por: Mousa, Youssef M., et al.
Publicado: (2020)

Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
por: Smith, Steve R., et al.
Publicado: (2008)

Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
por: Navarro, Carla, et al.
Publicado: (2022)

Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells
por: Hollomon, Mario G, et al.
Publicado: (2013)

Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death
por: Hollomon, Mario G., et al.
Publicado: (2020)

Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity
por: Dudek, Dorota, et al.
Publicado: (2022)

Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
por: Ando, Kosei, et al.
Publicado: (2013)

Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing
por: Kleinerman, Eugenie S., et al.
Publicado: (2018)

Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression
por: Safaeian, Leila, et al.
Publicado: (2022)

Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1
por: Markel, Justin E., et al.
Publicado: (2018)

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009)

Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide
por: Tyagi, Puneet, et al.
Publicado: (2022)

Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells
por: Bonuccelli, Gloria, et al.
Publicado: (2014)

Metabolic reprogramming in cancer: Mechanisms and therapeutics
por: Nong, Shiqi, et al.
Publicado: (2023)

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes
por: Riddle, M. C., et al.
Publicado: (2015)

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances meal-time glucagon suppression in diabetic pigs
por: Maikawa, Caitlin L., et al.
Publicado: (2020)

SIX4 upregulates IDH1 and metabolic reprogramming to promote osteosarcoma progression
por: Li, Bing, et al.
Publicado: (2023)

Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents
por: Stewart, Keri S., et al.
Publicado: (2011)

Metabolic Reprogramming in Kidney Diseases: Evidence and Therapeutic Opportunities
por: Li, Yin, et al.
Publicado: (2021)

Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis
por: Sheng, Gaohong, et al.
Publicado: (2023)

Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
por: Wang, Mengdi, et al.
Publicado: (2022)

Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3
por: Kuk, Myeong Uk, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dumoe1e382qeh7mioo4o7r578q